oxaprozin

Trade name: daypro

Small moleculeapproved

Approved

Oct 29, 1992

Oxaprozin is a nonsteroidal anti-inflammatory drug (NSAID) with analgesic and antipyretic properties. Anti-inflammatory effects of Oxaprozin are believed to be due to inhibition of cylooxygenase in platelets which leads to the blockage of prostaglandin synthesis. Antipyretic effects may be due to action on the hypothalamus, resulting in an increased peripheral blood flow, vasodilation, and subsequent heat dissipation. Oxaprozin is a non-selective NSAID, with a cell assay system showing lower COX-2 selectivity implying higher COX-1 selectivity. Oxaprozin is used to treat rheumatoid arthritis, osteoarthritis, dysmenorrhea, and to alleviate moderate pain. — NCATS

Clinical trial activity

1 trials · 2 clinical orgs · 14 marketing orgs

Phase 1

Phase 2

Phase 3

Phase 4

Earliest trial started Nov 2, 2017 (NCT03350386)

Timeline

1990s

Oct 29, 1992
G D Searle — Earliest FDA Approval
Oct 29, 1992
G D Searle — NDA Secondary Org
Oct 29, 1992
G D Searle — NDA Organization
Oct 29, 1992
Pfizer — Marketing Organization
Oct 29, 1992
Pfizer — NDA Secondary Org

2000s

Jan 31, 2001
Dr. Reddy's Laboratories — Marketing Organization
Jan 31, 2001
Sandoz — Marketing Organization
Jan 31, 2001
Novartis — Marketing Organization
Feb 9, 2001
Watson Pharmaceuticals — Marketing Organization
Feb 28, 2001
Mylan — Marketing Organization
Apr 12, 2001
Beximco — Marketing Organization
Oct 3, 2001
Actavis — Marketing Organization
Jan 3, 2002
Sun Pharmaceuticals — Marketing Organization
May 13, 2002
Teva — Marketing Organization
Sep 2, 2004
Apotex — Marketing Organization
Sep 2, 2004
Chartwell Pharmaceuticals — Marketing Organization

2010s

Jan 1, 2017
Earliest Phase 1 Sponsor(trial)
May 4, 2017
Amneal Pharmaceuticals — Marketing Organization

Indications

Approved for

Studied for

Healthy Volunteers · Phase 1

Mechanism of action

CyclooxygenaseINHIBITOR
Cyclooxygenase inhibitor
- Prostaglandin G/H synthase 2 (PTGS2) ↗
- Prostaglandin G/H synthase 1 (PTGS1) ↗
- Cyclooxygenase-1
- Cyclooxygenase-2

Approval history

approvedOct 29, 1992

Chemistry & pharmacology

Loading structure…

SMILES

O=C(O)CCc1nc(-c2ccccc2)c(-c2ccccc2)o1

Mol. weight: 293.32 g/mol
Lipinski Ro5: Pass
Rule of 3: No
Chirality: Achiral Molecule
Inorganic: No
Polymer: No
Delivery: Oral
Availability: Prescription Only

Oral

Yes

Parenteral

Topical

Black box warning

Sources

Also known as

4,5-diphenyl-2-oxazolepropionic acid
alvo
apo-oxaprozin
danoprox
danoprox
danoprox
daypro
daypro
daypro
daypro
daypro alta
daypro alta
dayrun
dayrun
dayrun
deflam
deflam
duraprox
duraprox
oxaprozin
oxaprozin
oxaprozin
oxaprozin
oxaprozin
oxaprozin
oxaprozin
oxaprozin
oxaprozin
oxaprozin
oxaprozina
oxaprozina
oxaprozine
oxaprozine
oxaprozin potassium
oxaprozin potassium
oxaprozin potassium
oxaprozin potassium
oxaprozinum
oxaprozinum
rhoxal-oxaprozin
walix
walix
wy 21743
wy-21743
wy-21743
wy-21,743

Clinical trials

NCT ID	Phase	Start date	Sponsor(s)
NCT03350386	Phase 1	Nov 2, 2017	Fuji Yakuhin Co., Ltd., Mochida Pharmaceutical Company, Ltd.

Showing 1 of 1 trials

Page 1 / 1

Organizations

Research & Development (2)

Organization	Org type	Trials	As lead sponsor	Phases	Earliest year
Fuji Yakuhin Co., Ltd.	For profit	1	0	1	2017
Mochida Pharmaceutical Company, Ltd.	For profit	1	1	1	2017

2 organizations

Page 1 / 1

Marketing (18)

Organization	Org type	Relationship	Date
Actavis	For profit	MKTG	Oct 3, 2001
Amneal Pharmaceuticals	For profit	MKTG	May 4, 2017
Apotex	For profit	MKTG	Sep 2, 2004
Beximco	For profit	MKTG	Apr 12, 2001
Chartwell Pharmaceuticals	For profit	MKTG	Sep 2, 2004
Dr. Reddy's Laboratories	For profit	MKTG	Jan 31, 2001
G D Searle	For profit	NDA2	Oct 29, 1992
G D Searle	For profit	NDA	Oct 29, 1992
Mylan	For profit	SYN	Aug 17, 2001
Mylan	For profit	MKTG	Feb 28, 2001
Novartis	For profit	MKTG	Jan 31, 2001
Pfizer	For profit	MKTG	Oct 29, 1992
Pfizer	For profit	NDA2	Oct 29, 1992
Sandoz	For profit	MKTG	Jan 31, 2001
Sun Pharmaceuticals	For profit	MKTG	Jan 3, 2002
Teva	For profit	MKTG	May 13, 2002
Teva	For profit	SYN	Jul 3, 2002
Watson Pharmaceuticals	For profit	MKTG	Feb 9, 2001